QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)
QQQ   439.00 (+0.86%)
AAPL   180.75 (-0.37%)
MSFT   413.64 (+1.45%)
META   490.13 (+1.26%)
GOOGL   138.46 (+1.53%)
AMZN   176.76 (+2.08%)
TSLA   201.88 (-0.08%)
NVDA   791.12 (+1.87%)
NIO   5.74 (+5.71%)
AMD   192.53 (+9.06%)
BABA   74.02 (-0.76%)
T   16.93 (-0.18%)
F   12.43 (+1.06%)
MU   90.61 (+1.00%)
CGC   3.29 (-2.08%)
GE   156.83 (+0.78%)
DIS   111.51 (+0.64%)
AMC   4.34 (-13.21%)
PFE   26.55 (-1.81%)
PYPL   60.34 (+0.15%)
XOM   104.52 (+0.19%)

Akari Therapeutics (AKTX) Competitors

$2.21
-0.01 (-0.45%)
(As of 02/29/2024 ET)

AKTX vs. LGVN, ORGS, ONTX, INDP, NRSN, BCEL, COCP, RNXT, NNVC, and MYNZ

Should you be buying Akari Therapeutics stock or one of its competitors? The main competitors of Akari Therapeutics include Longeveron (LGVN), Orgenesis (ORGS), Onconova Therapeutics (ONTX), Indaptus Therapeutics (INDP), NeuroSense Therapeutics (NRSN), Atreca (BCEL), Cocrystal Pharma (COCP), RenovoRx (RNXT), NanoViricides (NNVC), and Mainz Biomed (MYNZ). These companies are all part of the "pharmaceutical preparations" industry.

Akari Therapeutics vs.

Akari Therapeutics (NASDAQ:AKTX) and Longeveron (NASDAQ:LGVN) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

Longeveron has a consensus price target of $9.25, suggesting a potential upside of 1,583.04%. Given Longeveron's higher probable upside, analysts clearly believe Longeveron is more favorable than Akari Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Akari Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Longeveron
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

Akari Therapeutics has higher earnings, but lower revenue than Longeveron.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Akari TherapeuticsN/AN/A-$17.75MN/AN/A
Longeveron$767K17.98-$18.83M-$1.02-0.54

Akari Therapeutics has a beta of 1.04, indicating that its stock price is 4% more volatile than the S&P 500. Comparatively, Longeveron has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500.

Akari Therapeutics has a net margin of 0.00% compared to Longeveron's net margin of -3,020.17%. Akari Therapeutics' return on equity of 0.00% beat Longeveron's return on equity.

Company Net Margins Return on Equity Return on Assets
Akari TherapeuticsN/A N/A N/A
Longeveron -3,020.17%-187.76%-127.14%

Akari Therapeutics received 256 more outperform votes than Longeveron when rated by MarketBeat users. However, 85.71% of users gave Longeveron an outperform vote while only 55.74% of users gave Akari Therapeutics an outperform vote.

CompanyUnderperformOutperform
Akari TherapeuticsOutperform Votes
262
55.74%
Underperform Votes
208
44.26%
LongeveronOutperform Votes
6
85.71%
Underperform Votes
1
14.29%

In the previous week, Akari Therapeutics and Akari Therapeutics both had 7 articles in the media. Longeveron's average media sentiment score of 0.15 beat Akari Therapeutics' score of 0.07 indicating that Longeveron is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Akari Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Longeveron
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

3.8% of Longeveron shares are owned by institutional investors. 61.8% of Akari Therapeutics shares are owned by insiders. Comparatively, 24.3% of Longeveron shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Akari Therapeutics beats Longeveron on 7 of the 13 factors compared between the two stocks.


Get Akari Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for AKTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AKTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

AKTX vs. The Competition

MetricAkari TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$12.32M$6.59B$4.94B$7.48B
Dividend YieldN/A2.81%2.87%3.87%
P/E RatioN/A8.61217.8615.69
Price / SalesN/A1,085.773,209.89201.58
Price / CashN/A19.3194.4854.64
Price / Book4.544.754.464.68
Net Income-$17.75M$153.09M$112.73M$210.91M
7 Day Performance-2.68%6.38%4.91%2.78%
1 Month Performance-19.26%11.29%10.02%3.89%
1 Year Performance-68.41%5.75%12.58%8.07%

Akari Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LGVN
Longeveron
3.4993 of 5 stars
$0.53
-1.9%
$9.25
+1,661.9%
-84.1%$13.18M$1.22M-0.5419Short Interest ↓
News Coverage
ORGS
Orgenesis
4.2845 of 5 stars
$0.41
+2.5%
$6.00
+1,367.0%
-59.8%$13.04M$36.03M-0.45167Short Interest ↑
News Coverage
ONTX
Onconova Therapeutics
3.3635 of 5 stars
$0.68
+1.5%
$11.00
+1,515.3%
-3.4%$14.30M$230,000.00-0.7016Analyst Report
Short Interest ↓
News Coverage
INDP
Indaptus Therapeutics
3.1179 of 5 stars
$1.72
+5.5%
$12.00
+597.7%
+17.9%$14.45MN/A-0.956Short Interest ↑
Gap Up
NRSN
NeuroSense Therapeutics
0 of 5 stars
$1.33
-2.9%
N/A-6.2%$14.55MN/A-1.4114Positive News
Gap Up
BCEL
Atreca
4.3675 of 5 stars
$0.31
flat
$10.75
+3,334.5%
-81.2%$12.40MN/A-0.1390Short Interest ↓
Positive News
COCP
Cocrystal Pharma
2.1578 of 5 stars
$1.44
-8.3%
$10.00
+594.4%
-24.6%$14.65MN/A-0.6912Short Interest ↑
High Trading Volume
RNXT
RenovoRx
1.5821 of 5 stars
$1.38
flat
$8.50
+515.9%
-57.1%$14.75MN/A-1.4710Upcoming Earnings
Short Interest ↑
NNVC
NanoViricides
0 of 5 stars
$1.25
+1.6%
$5.25
+318.8%
+5.6%$14.77MN/A-1.557Analyst Report
Gap Up
MYNZ
Mainz Biomed
3.1491 of 5 stars
$1.01
flat
$7.00
+593.1%
-86.5%$12.13M$873,999.000.0058Short Interest ↓

Related Companies and Tools

This page (NASDAQ:AKTX) was last updated on 2/29/2024 by MarketBeat.com Staff